Evidence map›Paper›PMID 34164948›Full record

ReviewStem cells translational medicine2021

Inflammation, a common mechanism in frailty and COVID-19, and stem cells as a therapeutic approach.

José Becerra, Ivan Duran

Open access · goldAbstract readReview
In one paragraph

Review in Stem cells translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Frailty after COVID-19: The wave after?Aging medicine (Milton (N.S.W)) · 2023
    Review
  3. A Review of Extracellular Vesicles in COVID-19 Diagnosis, Treatment, and Prevention.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Review
  4. COVID-19 and Frailty.Vaccines · 2023
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

José BecerraDepartment of Cell Biology, Genetics, and Physiology, Faculty of Sciences, University of Málaga, IBIMA, Málaga, Spain.
Ivan DuranDepartment of Cell Biology, Genetics, and Physiology, Faculty of Sciences, University of Málaga, IBIMA, Málaga, Spain.ORCID 0000-0001-6097-0402
Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine · ES

Funding

Iniciativa Ingenio 2010, Consolider Program, CIBER Actions, the Instituto de Salud Carlos IIIJunta de Andalucia CV20-81404Junta de Andalucia UMA18-FEDERJA-177Regional Government of AndalusiaSpanish Network on Cell Therapy RD16/0011/0022University of Malaga (Plan Propio)
6 · The paper itself

Abstract

As our life expectancy increases, specific medical conditions appear, and new challenges are met in terms of global health. Frailty has become a medical and scientific concept to define pathologies where inflammation, depressed immune system, cellular senescence, and molecular aging converge. But more importantly, frailty is the ultimate cause of death that limits our life span and deteriorates health in an increasing proportion of the world population. The difficulty of tackling this problem is the combination of factors that influence frailty appearance, such as stem cells exhaustion, inflammation, loss of regeneration capability, and impaired immunomodulation. To date, multiple research fields have found mechanisms participating in this health condition, but to make progress, science will need to investigate frailty with an interdisciplinary approach. This article summarizes the current efforts to understand frailty from their processes mediated by inflammation, aging, and stem cells to provide a new perspective that unifies the efforts in producing advanced therapies against medical conditions in the context of frailty. We believe this approach against frailty is particularly relevant to COVID-19, since people in a state of frailty die more frequently due to the hyperinflammatory process associated with this infection.

Indexed as

COVID-19FrailtyMesenchymal Stem Cell TransplantationAgingHumansImmunomodulationInflammationMesenchymal Stem CellsRegenerationSARS-CoV-2Signal TransductionagingCOVID-19frailtyimmunomodulationinflammationmesenchymal stem cellMSCregenerationstem cell exhaustion

Identifiers

PMID34164948
PMCPMC8550702
OpenAlexW3176567637

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.